首页 正文

Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches

{{output}}
Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that... ...